Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 3Phase 3 2Phase 4 1

Status

Suspended 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2CNS 1

Conditions

Meningioma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 273Magnetic Resonance Spectroscopy 226pembrolizumab 218Carboplatin 174Biopsy 164Cisplatin 157Nivolumab 155Cyclophosphamide 139Radiotherapy 121Paclitaxel 120Gemcitabine 113durvalumab 90Bevacizumab 89Dexamethasone 82Rituximab 81Oxaliplatin 77venetoclax 73atezolizumab 70Doxorubicin 70Docetaxel 66Radiosurgery 65Fluorouracil 65Ipilimumab 64Capecitabine 64Etoposide 62Radiation 59Prednisone 59Cytarabine 59Lenalidomide 56fludarabine 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Hydroxyurea × 90 days × Clear all
NCT06955169 2026-05-22

MOMENTUM-1

RTOG Foundation, Inc.

Phase 2 Suspended
153 enrolled
CNS

Meningioma

NCT06930352 2026-03-13

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Ohio State University Comprehensive Cancer Center

Phase 2 Not yet recruiting
70 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07033598 2026-03-05

PROSPERA

Theradex

Phase 2 Recruiting
66 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡